Exagen Inc. announced that on December 5, 2022, Debra Zack, M.D., Ph.D., the company's Chief Medical Officer, was removed from her position and her employment terminated in connection with the Reduction in Force. Dr. Zack is entitled to severance under that certain Amended and Restated Executive Change in Control and Severance Plan. On December 5, 2022, Mark Hazeltine, the Company's current Chief Operating Officer was appointed to serve as the Company's Chief Business Officer.

Mr. Hazeltine has served as the company's Chief Operating Officer since March 2021 and served in multiple key leadership roles including General Manager, Senior Vice President of Finance and Corporate Development, Vice President of Finance, and Senior Director of Financial Planning and Analysis since joining the Company in March 2015. Prior to joining the Company, from September 2010 to March 2015, Mr. Hazeltine served as Director of Financial Planning and Analysis and Director of Financial Business Processes at CareFusion. Mr. Hazeltine also worked in multiple management roles at multinational organizations including Kyocera and Qualcomm.

Mr. Hazeltine received a B.A. in Business Administration from the University of San Diego and an M.B.A. from the Marshall School of Business at the University of Southern California.